Behavioral and Self-Report Cognitive Impairment Differences between Fast-Acting, Standard, and Placebo Cannabis...

Fast-acting edible cannabis products are marketed as producing quicker effects than standard edibles, but whether faster absorption translates into earlier cognitive impairment due to cannabis intoxication is unclear.

We compared fast-acting, standard, and placebo edibles in a double-blind, within-subject crossover study of 20 adult individuals who frequently use cannabis.

Participants completed three mobile laboratory sessions after ingesting either a fast-acting, standard, or placebo cannabis edible and were assessed repeatedly over 270 minutes using the DRUID impairment app and selected self-report items from the Subjective High Assessment Scale (SHAS).

Mixed-effects models showed limited evidence that the fast-acting edible produced significantly earlier impairment than the standard edible. Behavioral impairment showed no clear pattern over time. Self-reported effects were more consistent across both active edibles, with elevations in clumsiness, distorted time perception, and other subjective impairment outcomes relative to placebo. However, the fast-acting and standard edibles generally showed similar time courses, with little evidence of a meaningful advantage for the fast-acting formulation.

Both active edibles produced several hours of subjective impairment, but the fast-acting product did not consistently yield significantly earlier cognitive effects than the standard edible.